Business
Ainos Reports Second Quarter 2023 Financial Results
Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered TestingLaunch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos
About this update from Ainos, Inc.
[{"type":"text","content":"Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered TestingLaunch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains on Horizon for 2024SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\", or the \"Company\"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the second quarter ended June 30, 2023.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, \"The second quarter of 2023 was a transitionary period for our company. We forged ahead with a recalibrated strategic approach, shifting our focus away from COVID and into new and promising product categories. Our latest volatile organic compound (VOC) co-development initiative for our VOC sensing platform, the recent launch of VELDONA® Pet, and our progress in the development of Ainos Flora have underpinned this transformation.\"\"In June, we successfully launched our VELDONA® Pet cytoprotein health supplement line in Taiwan to initiate our strategy to address the growing global pet care market. Next step, we intend to explore commercial opportunities for VELDONA® Pet in other markets over the coming months, and target US$20 million in sales of the product line in 2024. VELDONA® Pet consists of five products addressing a variety of health needs for cats and dogs associated with skin, gum, eye, stress, and weight. The products provide us with an opportunity to diversify our revenue streams and catalyze our future growth, while playing a key role in generating and accelerating returns on nearly four decades of investment in our VELDONA® platform. We also plan to continue exploring out-licensing opportunities for VELDONA® for six human indications.\"\"Meanwhile, we have made additional progress in the development of Ainos Flora. Flora is our flagship VOC POCT device, which utilizes our innovative AI Nose technology to quickly and discreetly test for vaginal infection and certain common STIs. Ainos Flora is undergoing clinical trials at four major medical centers in Taiwan. We expect these trials will conclude by the end of 2023, positioning us to advance the device towards commerc...